Trainings and Resources
24 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/24/2022 (updated 9/14/2022)
Almost two-thirds of people currently incarcerated in the U.S. have a substance use disorder. Many struggle with opioid addiction. Opioids include prescription pain relievers, heroin, and powerful synthetic versions such as fentanyl that are driving record numbers of overdose deaths. Men in a rural jail who received medication to treat opioid use disorder had a reduced likelihood of being arrested or returning to jail or prison after release. The results need to be replicated in larger, more diverse populations, but they suggest the promise of drug treatment in helping to reduce reincarceration.
Posted 10/20/2021 (updated 8/24/2022)
Justice-involved populations are disproportionately affected by the opioid and overdose crisis. In fact, people who have been incarcerated are roughly 129 times more likely to experience a fatal overdose in the first two weeks after their release compared to the general public due to reduced tolerance during incarceration.1 Despite the fact that evidence-based medication for opioid use disorder (MOUD) is the standard of care in the community, and has been proven to reduce risk of overdose and mortality, it remains widely unavailable in most correctional facilities. However, that is slowly changing. Correctional staff, medical professionals, incarcerated individuals and politicians are beginning to advocate for MOUD. JPOP aims to address the need for accessible information about medication-based treatment for opioid use disorder in the criminal legal system. We encourage you to engage with the resources and tools and links on this website to help to improve treatment for opioid use disorder in your community
Posted 3/21/2022 (updated 8/17/2022)
This spreadsheet details states’ publicly reported, opioid settlement-related state-subdivision agreements, statutory trusts, and allocation statutes. It was completed with assistance from the Johns Hopkins Bloomberg School of Public Health (Principles for the Use of Funds From the Opioid Litigation).
Posted 4/6/2022 (updated 8/17/2022)
Through the Opioid Risk Prevention Partnership, SCMA is sharing resources to help physicians and clinical care teams facilitate conversations with patients who have acute pain, chronic pain, and addiction. The Partnership aims to support medical providers’ efforts to have conversations with patients about pain, and the appropriate use of alternatives to opioids in pain management.
Posted 4/12/2022 (updated 8/17/2022)
Describes the work of 26 2018-2021 Rural Health Opioid Program (RHOP) grantees in addressing the opioid epidemic through community-based consortiums. Highlights each project's achievements and identifies common themes of program impact.
The Bureau of Justice Assistance (BJA), Centers for Disease Control and Prevention (CDC), National Association of Counties, and State Justice Institute (SJI) are co-sponsoring the Reaching Rural: Advancing Collaborative Solutions initiative. BJA, CDC, and SJI are supporting this initiative as part of an ongoing interagency partnership to strengthen public safety and public health collaboration under BJA’s Comprehensive Opioid, Stimulant, and Substance Abuse Program.
Posted 3/2/2022 (updated 7/19/2022)
The Centers for Disease Control and Prevention (CDC) is in the process of updating the 2016 guidelines and values feedback from health care professionals and members of the public who experience acute or chronic pain.
Posted 6/3/2022 (updated 6/14/2022)
The opioid settlement is a significant opportunity to improve substance use disorder prevention, treatment, and recovery. By attending to the evidence base and leveraging other funding sources, we can transform our behavioral health system to work better for people with substance use disorder. The Steadman Group related their experience in facilitating opioid settlement governance so you can optimize your settlement spending!
The goal of treatment for opioid addiction or opioid use disorder (OUD) is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential.1 This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.
The Substance Abuse and Mental Health Services Administration-funded Opioid Response Network (ORN) initiative has launched the Stand Against Stigma (SAS) Challenge. This is an opportunity for those in the healthcare industry to address and dispel stigma related to individuals with substance use disorders through easy, daily activity.